Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

Rheumatoid Arthritis Clinical Trial

Official title:

A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00367211
• Other study ID #: PN200-301
• Status: Completed
• Phase: Phase 3
• First received: August 18, 2006
• Last updated: April 21, 2008
• Start date: September 2006
• Est. completion date: September 2007

Study information

• Verified date: April 2008
• Source: POZEN
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the incidence of gastric ulcers following administration of either PN 200 or Naproxen in subjects who are at risk for developing NSAID-associated ulcers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: September 2007
• Est. primary completion date: September 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or non-pregnant female subjects with a history of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis or other medical conditions expected to require daily NSAID therapy for at least 6 months who are 18-49 years of age and have a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years OR, who are 50 years of age and older (these subjects do not require a history of a documented, uncomplicated gastric or duodenal ulcer within the past 5 years).

• Female subjects are eligible for participation in the study if they are of:

1. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or,

2. Childbearing potential, have a negative pregnancy test (urine) at screening, and at least one of the following applies or is agreed to by the subject:

• Complete abstinence from intercourse for at least 14 days prior to first dose of study drug, throughout the study, and for 30 days after completion of the study

• Female sterilization or sterilization of male partner; or,

• Hormonal contraception by oral route, implant, injectable, vaginal ring; or,

• Any intrauterine device (IUD) with published data showing that the lowest expected failure rate is less than 1% per year;

• Double barrier method (2 physical barriers or 1 physical barrier plus spermicide); or

• Any other method with published data showing that the lowest expected failure rate is less than 1% per year.

• Each subject must be able to understand and comply with study procedures required of a subject and is able and willing to provide written informed consent prior to any study procedures being performed.

Exclusion Criteria:

• History of hypersensitivity to omeprazole or to another proton-pump inhibitor.

• History of allergic reaction or intolerance to any NSAID (including aspirin) and/or subject has a history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps.

• Participation in any study of an investigational treatment in the 4 weeks before screening.

• Presence of uncontrolled acute or chronic medical illness, e.g. gastrointestinal disorder, diabetes, hypertension, thyroid disorder, depression and/or infection that would endanger a subject if they were to participate in the study.

• Gastrointestinal disorder or surgery leading to impaired drug absorption.

• Evidence of uncontrolled, or unstable cardio- or cerebrovascular disorder, which in the investigator's opinion would endanger a subject if they were to participate in the study.

• Schizophrenia or bipolar disorder.

• Use of any excluded concomitant medication (see Section 9.2).

• A recent history (in the past 3 months) suggestive of alcohol or drug abuse or dependence, including overuse/abuse of narcotics for management of pain.

• Serious blood coagulation disorder including use of systemic anticoagulants.

• Positive test result for H. pylori at screening.

• Baseline endoscopy showing any gastric or duodenal ulcer at least 3 mm in diameter with depth.

• Screening laboratory value for ALT, AST >2 times the upper limit of normal.

• Estimated creatinine clearance < 30 ml/min.

• Other than noted specifically, any screening laboratory value that is clinically significant in the investigator's opinion and would endanger a subject if they were to participate in the study.

• History of malignancy, treated or untreated, within the past 5 years, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Ankylosing Spondylitis
• Arthritis, Rheumatoid
• Osteoarthritis
• Rheumatoid Arthritis
• Spondylitis
• Spondylitis, Ankylosing
• Stomach Ulcer

Intervention

Drug:
• PN 200 tablets (500 mg naproxen and 20 mg omeprazole)

• Naproxen 500 mg tablets (PN 200 minus omeprazole)

Locations

Country	Name	City	State
United States	Patient Interaction	Pompano Beach	Florida

Sponsors (1)

Lead Sponsor	Collaborator
POZEN

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary efficacy variable is the incidence of gastric ulcers, defined as a mucosal break of at least 3 mm in diameter (measured by close application of open endoscopic biopsy forceps) with depth, at anytime throughout 6 months of study treatment.
Secondary	The secondary efficacy variable is the incidence of duodenal ulcers at any time throughout 6 months of treatment, tolerability and safety.